Atezolizumab for previously untreated recurrent or advanced non-small cell lung cancer unsuitable for platinum-doublet chemotherapy

Atezolizumab is in development for the treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) who are deemed unsuitable for platinum-doublet chemotherapy. NSCLC is the most common form of lung cancer. Metastatic NSCLC describes tumours that have spread from the lungs to other parts of the body. Smoking tobacco is the cause of most lung cancers and the biggest risk factor. Other risk factors include second-hand smoke, exposure to workplace carcinogens, radiation exposure, environmental pollution, and family history of lung cancer. Current standard of care treatment can help to control the cancer for some time and reduce symptoms, however, sometimes NSCLC can continue to grow despite chemotherapy and immunotherapy.